Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cancer Res Treat. 2005 Feb;37(1):31-6. doi: 10.4143/crt.2005.37.1.31. Epub 2005 Feb 28.
The 10-year overall survival rate following conventional treatments for patients with limited-stage Hodgkin's disease (HD) exceeds 90%. However, the clinical features and treatment outcome of HD in Korea have not been extensively characterized due to its low incidence. In this study, we attempted to analyze the treatment outcome of different modalities in limited stage HD patients.
Twenty one Hodgkin's disease patients, referred to the Samsung Medical Center between January 1997 and December 2003, were enrolled in this study. Limited stage Hodgkin's disease was subdivided into low and high risk groups. All evaluable patients received treatment.
There were 13 and 8 patients in the low and high risk groups, respectively. Eighteen patients (86%) obtained complete response (CR) and 3 patients (14%) achieved an undetermined complete response (CRu). Fourteen (67%), 4 (19%) and 3 (14%) cases received combination chemotherapy, radiotherapy alone and chemotherapy alone, respectively. Four cases relapsed and 2 obtained a second CR. The 5-year overall and disease-free survival rates were 90 and 72%, respectively, for all patients. The median follow-up duration was 31 months. There was no difference in disease free survival (DFS) between the low and high risk groups. Although 12 cases had neutropenia greater than grade III, none experienced neutropenic fever.
The treatment outcome of limited-stage HD was excellent, regardless to the initial treatment modality.
接受局限期霍奇金病（HD）传统治疗的患者，10 年总生存率超过 90%。然而，由于其发病率较低，韩国 HD 的临床特征和治疗结果尚未得到广泛描述。本研究旨在分析局限期 HD 患者不同治疗方式的治疗结果。
1997 年 1 月至 2003 年 12 月期间，21 例霍奇金病患者被转诊至三星医疗中心，这些患者被纳入本研究。局限期 HD 进一步分为低危组和高危组。所有可评估患者均接受了治疗。
低危组和高危组分别有 13 例和 8 例患者。18 例（86%）患者获得完全缓解（CR），3 例（14%）患者获得未确定的完全缓解（CRu）。14 例（67%）、4 例（19%）和 3 例（14%）患者分别接受了联合化疗、单纯放疗和单纯化疗。4 例患者复发，2 例获得了第二次 CR。所有患者的 5 年总生存率和无病生存率分别为 90%和 72%。中位随访时间为 31 个月。低危组和高危组无病生存率（DFS）无差异。尽管 12 例患者中性粒细胞减少症大于 3 级，但均未发生中性粒细胞减少性发热。
无论初始治疗方式如何，局限期 HD 的治疗结果均良好。
